Jr. Jeng et al., PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND ANGIOTENSIN-I-CONVERTING-ENZYMEGENE POLYMORPHISM IN PATIENTS WITH HYPERTENSION, American journal of hypertension, 11(2), 1998, pp. 235-239
Deletion polymorphism of angiotensin I-converting enzyme (ACE) gene ha
s been reported to be an independent risk factor for myocardial infarc
tion. Plasminogen activator inhibitor-1 (PAI-1) was proposed to be a l
ink between the renin-angiotensin system and thrombotic risk. This stu
dy was undertaken to investigate the possible association between the
insertion/deletion (I/D) polymorphism of the ACE gene and plasma PAI-1
levels in 160 patients with mild-to-moderate hypertension. The I/D ge
notypes were determined by polymerase chain reaction with oligonucleot
ide primers flanking the polymorphic region in intron 16 of the ACE ge
ne. Baseline levels of PAI-1 antigen and activity and tissue plasminog
en activator (t-PA) antigen were determined in fasting morning plasma
samples. It was found that patients with homozygote deletion (DD, n =
37) ACE genotype did not have significantly higher plasma levels of PA
I-1 antigen (31.2 +/- 15.6 ng/mL v 28.4 +/- 15.1 ng/mL or 27.2 +/- 13.
2 ng/mL, P = .42), PAI-1 activity (16.2 +/- 10.6 IU/mL v 14.1 +/- 9.4
IU/mL or 15.0 +/- 9.9 IU/mL, P = .60), or t-PA antigen (14.6 +/- 6.0 n
g/mL. v 13.4 +/- 4.9 ng/mL or 14.6 +/- 5.7 ng/mL, P = .40) as compared
to those with heterozygote (DI, n = 67) or homozygote insertion (II,
n = 56) genotypes. On multiple regression analysis, the ACE genotypes
did not appear to be significant predictors for plasma PAI-1 levels an
d t-PA antigen after adjustment with age, sex, body mass index, plasma
triglyceride, cholesterol, and glucose. In conclusion, the results in
dicated that the I/D polymorphism of the ACE gene was not related to p
lasma PAI-1 levels in a Chinese population with hypertension. The ACE
genotypes may not have a role in influencing the fibrinolysis in hyper
tension. (C) 1998 American Journal of Hypertension, Ltd.